Investing

DBV Technologies : DBVT

DBVT

Stock Data

$19.87

$1.13 (5.38%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

DBV Technologies SA (DBVT) is a pioneering biopharmaceutical company headquartered in Montrouge, France, focused on revolutionizing food allergy treatment through its proprietary Viaskin™ technology platform. As a clinical-stage organization, DBV is dedicated to developing non-invasive epicutaneous immunotherapies aimed at promoting allergen desensitization, with a primary focus on peanut allergies. The company is currently advancing a robust pipeline through a series of clinical trials, positioning itself as a leader in addressing significant unmet medical needs in allergy management while striving to improve patient quality of life.

All DBV Technologies Articles

2 Articles

Lee Jackson | Dec 15, 2025 at 8:16 AM EST

Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More

Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All…

Lee Jackson | Dec 3, 2025 at 8:15 AM EST

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day…